Publications

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study

DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…

FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology

New sample preparation method enabling PCR-based pathogen identification directly from blood to accelerate blood stream infection (BSI) diagnosis

Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…

Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio…

Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123

DEBIO 1143, an IAP inhibitor, reverses ovarian cancer cells carboplatin resistance and triggers apoptotic or necroptotic cell death